Evolution of heat tolerance and drug resistance in Cryptococcus
Project Number1DP2AI184725-01
Contact PI/Project LeaderBILLMYRE, ROBERT BLAKE
Awardee OrganizationUNIVERSITY OF GEORGIA
Description
Abstract Text
Project Summary
Environmental microbes are affected by and evolve to succeed in the changing environments they inhabit. As
a result, changes in the environment can select for microbes that are more or less capable of causing human
infections. Cryptococcus is a genus of opportunistic fungal pathogens that cause approximately 200,000
deaths in HIV/AIDS individuals. Cryptococcus species grow in an environmental niche before causing
“accidental” infections of mammals with no known return to the environment after infection or spread between
hosts. Notably, the pathogens within the genus split from the nonpathogens approximately 100 million years
ago, concurrent with the development of the ability to grow at human body temperature. In the proposed work,
I will use the Cryptococcus genus to explore the genetic basis of two pathogenesis relevant traits that are
changing in the environment because of human activities, with an eye towards using Cryptococcus as a model
to understand how these changes in environment may alter other environmental fungi. Project 1 will focus on
the transition to thermotolerance that occurred in the Cryptococcus genus. Elevated global temperatures as a
result of climate change will likely select for environmental microbes that can grow at higher temperatures. I will
employ high-throughput genetics approaches (TN-seq) to characterize genome-wide contributions to growth at
various temperatures across the entire Cryptococcus genus, including both pathogens and nonpathogens. I
will then use allele swap experiments to explore effects of sequence variation, lineage-specific gene content,
and transcriptional reprogramming. Project 2 will focus on resistance to azole class drugs. Modern agricultural
practices employ large amounts of azole drugs to control fungal plant pathogens. Environmental fungi are also
commonly exposed to these drugs and thus are being selected for drug resistance. I will use a diploid complex
trait genetics approach (RH-seq) that is based on TN-seq to explore the basis of azole drug resistance in a
large (n=387) strain collection of environmental and clinical isolates from Africa. I will again use allele swap
experiments to validate drug resistance mutations and test the contribution of epistasis to antifungal drug
resistance. This work will reveal fundamental mechanisms underlying adaptation to high temperatures and
antifungal drugs. It will also generate mutant libraries across an entire genus and mapping populations for a
large number of C. neoformans isolates that can be used in future projects across the community. An
expanded understanding of heat tolerance and of drug resistance may aid in the development of novel
antifungal agents or more efficient use of the currently available drugs, leading to improved outcomes for
treatment of invasive fungal diseases. Finally, a better understanding of how human activities lead to changes
in environmental microbes can provide both predictions and potential guidance for intervention.
Public Health Relevance Statement
Narrative
Many pathogens live in the environment prior to encountering a mammalian host. As a result, human
interactions with the environment can alter the population of pathogens we are likely to encounter and thus
with which we are infected. This proposal aims to understand how heat tolerance and drug resistance are
controlled by genetic variation at two different time scales (across a genus and within a species) of
opportunistic environmental fungal pathogens in order to better predict how pathogens are likely to be altered
by human activities.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
004315578
UEI
NMJHD63STRC5
Project Start Date
12-August-2024
Project End Date
31-July-2029
Budget Start Date
12-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$443,944
Direct Costs
$300,000
Indirect Costs
$143,944
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$443,944
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1DP2AI184725-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2AI184725-01
Patents
No Patents information available for 1DP2AI184725-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2AI184725-01
Clinical Studies
No Clinical Studies information available for 1DP2AI184725-01
News and More
Related News Releases
No news release information available for 1DP2AI184725-01
History
No Historical information available for 1DP2AI184725-01
Similar Projects
No Similar Projects information available for 1DP2AI184725-01